330 Index Name Paper ref. Name Paper ref. Ferreira, HHA Mon 289 Ferreira, S Mon 275 Ferreira, W Mon 095, Mon 097, Mon 094 Ferreirinha, F Thu 064 Ferro, H Mon 280 Feske, S FC12.5.3 Festa, M Tue 406 Fey, V Mon 410, Tue 436 Fickl, H Mon 368 Field, J Mon 102 Figueiras, A Thu 119, Tue 086, Mon 146 Figueiredo, C Wed 302, Tue 428 Figueiredo, I Wed 214, Mon 299, Mon 298, Wed 319 Figueiredo, IV Mon 376, Thu 119 Figueirinha, A Mon 291 Figueiró, M FC16.2.3 Figura, P Thu 174 Filali, H Mon 290, Mon 378, Mon 377 Filaretova, L W02.2.5 Filipcsei, G Tue 130 Filipovic, B Mon 096 Filippov, AK Wed 047 Filiz Basaran, N Wed 179 Filppula, A Mon 380 Finch, AM Mon 394, Wed 032, Wed 048 Finetti, F Wed 243 Fingerhut, R Wed 016 Fioravanzo, E Thu 433 Firenzuoli, F Thu 302 Firstova, J Wed 426 Firuzi, O Thu 309 Fischer, DF W14.4 Fischer, J Thu 197 Fischer, M Tue 169 Fish, R Mon 393, Wed 020, Mon 420 Flacco, N Wed 068 Flammer, A FC16.1.2 Flammini, L Tue 258, Mon 381 Fleckenstein, L Tue 012 Flioni, E Tue 141 Flor, H W03.6 Flordellis, C Wed 074 Floreani, M Wed 404 Flores, ML Wed 350 Flores-Morales, A Tue 387, Tue 391, Tue 392 Flores-Murrieta, F Mon 009, Mon 019 Flores-Santana, W FC09.3.3 Flower, K FC14.2.5, Mon 388, Wed 170 Flower, RJ FC09.4.6 Flynn, C Wed 158 Fogli, S Wed 442, Mon 382 Fois, C Tue 133 Fok, BSP FC02.4.6, Tue 140 Folarin, OA YI.09 Folkerts, G FC09.5.2 Folmes, CD FC05.2.6 Foltin, V Mon 479 Foltinova, J Thu 211, Thu 354 Fonseca, D Wed 337 Fontana, P Mon 337 Fontes Ribeiro, C Wed 140, Wed 180 Foo, Y-T FC01.3.1 Ford, L Tue 284 Forget, A FC04.1.5 Forjasz, R Mon 262 Formigos, JA Mon 138, Mon 472, Thu 407, Formigós-Bolea, J Mon 477, Mon 473, Mon 481 Fors, M Thu 394 Forsberg, M Mon 425 Förstermann, U FC15.4.3 Fortes, R Tue 008, Thu 322, Thu 321 Fortes, ZB Wed 233, FC06.1.5 Fortin, A Tue 396 Fortuna, A Thu 169, Mon 383, Tue 407 Fotoohi, A Mon 055 Fotouhi, M Mon 036 Fouad, M Mon 164 Foulquier, S Wed 244 Fourrier-Réglat, A FC04.4.6, W10.4 Frade, M Mon 298 Fraga, C Mon 398 Fraga, CAM Mon 279 Frame, F Tue 270 Francetic, I FC01.3.7, Mon 135, Mon 373, Tue 328 Francisco, V Mon 291 Franco, DW W31.3 Franco, LAM Mon 292 Frank, D Mon 384, Mon 315 Frank, E Thu 308 Frank, L Wed 092 Frankic, T Wed 171, Wed 004 Franks, N FC03.4.1 Franova, S Mon 293 Fransen, P Wed 246, Wed 245 Frappier, M Wed 123, Tue 051 Frau, A Tue 133 Frazziano, G Thu 217 Fredberg, U Tue 358 Fredericia, PM Tue 248 Free, R Thu 063 Freeman, D Wed 013 Freeman, DJ FC10.2.5 Freilij, H Mon 003, Wed 003 Freire, C Thu 366 Freire-Garabal, M Thu 325 Freissmuth, M FC11.4.5 Freitas, A Mon 275 Freitas, L Mon 298 Fresco, P Mon 126, Thu 054 Frey II, WH YI.02 Frey, N FC07.2.2 Freyer, J Tue 049 Frias, J Mon 451 Frías-Iniesta, J Tue 348 Friberg, L W29.3 Frigerio, C Wed 337 Frigerio, F Wed 447 Fröbert, O Thu 222 Frølund, B FC11.5.6 Fromm, MF FC02.2.6, FC02.3.2 Frotscher, M Tue 442 Fry, C H FC08.3.2 Fu, J Tue 419, Thu 440 Fu, S-Y Wed 035 Fu, W-M Wed 403 Fu, X Tue 384
Name Paper ref. Name Paper ref. Fuad, WEM Thu 312 Füchtbauer, EM FC02.3.6 Fürjes, G Tue 125 Fürst, R Tue 227, FC16.1.5 Fürst, S Wed 185, Thu 192 Fuhr, U Mon 315, Mon 384, Thu 010 Fujibayashi, M Wed 422, Wed 415 Fujii, M Tue 154 Fujii, A Tue 201, Tue 432 Fujii, N FC05.2.6 Fujimori, A Thu 416 Fujimura, A Thu 268, Wed 189 Fujimura, S Wed 189 Fujisawa, S Tue 430 Fujita, A Tue 234 Fujita, K Wed 141 Fujiwara, H Thu 261 Fujiwara, Y Wed 189 Fukami, K Mon 243 Fukasawa, T Wed 136 Fukazawa, I Tue 345 Fukuda, K FC13.2.5, Tue 126, Tue 260 Fukuhara, Y Wed 247 Fukui, H Wed 061 Fukuishi, N Mon 253 Fukumoto, A FC16.4.6 Fukunaga, K Thu 406 Fukushima, T Mon 307 Fulga, I Mon 111, Mon 274 Fuller, PJ FC18.2.3 Funaki, Y Tue 166 Fung, KP Thu 297, Wed 345 Funk, C Wed 235 Furlan, G Mon 385 Furlotti, G Mon 296 Furman, C Thu 063 Furuie, H Mon 386 Furukawa, K-I Tue 430 Furumoto, S FC17.5.6 Furuno, T Wed 422 Furuta, T W23.4, Tue 159, Mon 459, Tue 473 Furuta, Y Thu 406 Fusco, FB Wed 203, Mon 257 Fuster, JJ W09.4 Gaasemyr, J Tue 143 Gabrielsen, M Mon 224 Gacar, G Mon 387 Gacar, N Wed 351, Mon 387, Tue 145 Gad, M FC06.2.6 Gaedigk, A Mon 384 Gaetani, S Thu 440 Gagiano, C FC14.5.5 Gahrn-Hansen, B FC13.1.5 Gaïes, E FC07.3.6, Mon 020, Mon 021 Gailly, P Wed 102 Gajski, G Tue 447 Galán, J Tue 103 Galasso, L Tue 487 Galasso, R Tue 487 Gales, C Mon 162 Galindo, P Wed 268 Galione, A Wed 268 Gallardo, E Tue 144 Gallardo-Ortiz, I Wed 049 Galleyrand, J Mon 203, Mon 201, Mon 205, Mon 204 Gallo, C W04.3.2, Wed 102 Gallo, E Thu 302 Galloway, GP FC14.2.5, Mon 388, Wed 170 Gallwitz, B FC05.3.3 Galuppo, M FC18.1.5, Mon 277, FC18.3.6 Gambassi, G FC04.4.5 Gammeltoft, S Wed 070, Thu 058, Wed 036 Gan, SH Mon 361, Mon 389, Tue 153, Tue 164, Tue 408, Tue 434, Tue 455 Ganafa, AA Tue 209 Gandelman, K Mon 251 Gandhi, T FC16.1.6 Ganpathy, P Mon 166, Tue 131 Ganshina, T Wed 248 Gantumur, M Tue 095 Gao, C Mon 056 Gao, D-L Mon 470 Gao, J Thu 377, Thu 242 Gao, J-W Mon 031 Gao, L Mon 434, Tue 181 Gao, M Mon 421 Gao, X Thu 371 Gao, X Tue 419 Gao, XM Wed 242 Gao, Y Tue 178, Wed 291, Thu 089 Gao, Y Tue 388 Gao, Z Mon 331 Gao, Z-Y Tue 082 Garaj-Vrhovac, V Tue 447 Garayt, C FC04.2.5 Garcia Fuentes, JL Mon 390 García -Gonzalez, D Wed 349 García Mondragón, MJ Thu 330 García Sacristán, A Wed 224 García, A Tue 042 Garcia, AG FC12.1.6 García, AG FC16.2.5, Mon 079 Garcia, MR Mon 038 Garcia, R Mon 207 Garcia, TSL Wed 204 Garcia-Algar, O Mon 375 Garcia-Arnes, JA Mon 471 Garcia-Barreto, D Mon 207 Garcia-Bournissen, F FC10.5.3, Mon 003, Mon 022, Wed 003, García-Cabanes, MC Mon 472, Mon 473, Mon 477, Mon 481 García-Carrascal, L Mon 149 García-Gimenez, D Tue 409 García-Iglesias, B Thu 265 Garcia-M, E Wed 109 Garcia-Ratés, S Thu 179 Garcia-Rates, S Wed 181 Garcia-Rivera, D Wed 344 Garcia-Rodriguez, C Mon 291 García-Sacristán, A Thu 249, Mon 239, Tue 213, Mon 411, Wed 225 García-Villalón, AL Wed 224 Gard, P Wed 409 Index 331
- Page 1:
of basic and clinical pharmacology
- Page 4 and 5:
Congress patron 2 HRH Crown Princes
- Page 6 and 7:
Congress President Kim Brøsen Secr
- Page 8 and 9:
General information Registration &
- Page 10 and 11:
Banks, currency & credit cards The
- Page 12 and 13:
Information to presenters ■ The a
- Page 14 and 15:
Hotel Bella Center Copenhagen Groun
- Page 16 and 17:
Programme at a glance Time Hall A2
- Page 18 and 19:
16 General events General events Op
- Page 20 and 21:
Programme outline Plenary lectures
- Page 22 and 23:
FC10 Drugs for half the world: Paed
- Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
- Page 26 and 27:
W01 Pharmacology of adrenoceptors:
- Page 28 and 29:
W02 Symposium on advances in GI pha
- Page 30 and 31:
W04 Symposium: Antioxidants as ther
- Page 32 and 33:
Plenary lectures PL01 Plenary lectu
- Page 34 and 35:
FC02 Transmembrane transport: Persp
- Page 36 and 37:
FC04 Pharmacoepidemiology, current
- Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
- Page 40 and 41:
FC09 Inflammation and immunopharmac
- Page 42 and 43:
W02 Symposium on advances in GI pha
- Page 44 and 45:
SS01 Sponsored symposium Sponsored
- Page 46 and 47:
W06 Workshop. Effect of disease on
- Page 48 and 49:
W08 Workshop. Identifying targets f
- Page 50 and 51:
W10 Workshop. Innovative Medicines
- Page 52 and 53:
FC01 Clinical pharmacology in the e
- Page 54 and 55:
FC03 Ion channels in analgesia and
- Page 56 and 57:
FC05 Translational science in the m
- Page 58 and 59:
FC06 The heart gone wrong: Stabiliz
- Page 60 and 61:
FC08 Development in the treatment o
- Page 62 and 63:
Plenary lectures PL04 Plenary lectu
- Page 64 and 65:
FC01 Clinical pharmacology in the e
- Page 66 and 67:
FC03 Ion channels in analgesia and
- Page 68 and 69:
FC05 Translational science in the m
- Page 70 and 71:
FC07 Simulation and data modelling
- Page 72 and 73:
FC09 Inflammation and immunopharmac
- Page 74 and 75:
W12 Workshop. Experimental pain met
- Page 76 and 77:
W14 Workshop. Translating the human
- Page 78 and 79:
W15 Workshop. The IUPHAR initiative
- Page 80 and 81:
W17 Workshop. Standards for PhD Edu
- Page 82 and 83:
W19 Workshop. Influence of degenera
- Page 84 and 85:
FC02 Transmembrane transport: Persp
- Page 86 and 87:
FC04 Pharmacoepidemiology, current
- Page 88 and 89:
FC06 The heart gone wrong: Stabiliz
- Page 90 and 91:
FC08 Development in the treatment o
- Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
- Page 94 and 95:
FC10 Drugs for half the world: Paed
- Page 96 and 97:
FC12 Ion channelopathies: New windo
- Page 98 and 99:
FC14 Addiction and doping: Neurobio
- Page 100 and 101:
FC17 New approaches and targets in
- Page 102 and 103:
W04 Symposium: Antioxidants as ther
- Page 104 and 105:
W21 Workshop. Inflammation - here,
- Page 106 and 107:
W23 Workshop. Applying pharmacogeno
- Page 108 and 109:
W25 Workshop. High science in the l
- Page 110 and 111:
W27 Workshop. Approaches to medicin
- Page 112 and 113:
FC11 G protein-coupled 7TM receptor
- Page 114 and 115:
FC13 Maximising benefits and minimi
- Page 116 and 117:
FC15 Endothelium in Health and dise
- Page 118 and 119:
FC17 New approaches and targets in
- Page 120 and 121:
FC18 Nuclear receptor targets for t
- Page 122 and 123:
PL16 Plenary Lecture Supported by a
- Page 124 and 125:
FC11 G protein-coupled 7TM receptor
- Page 126 and 127:
FC13 Maximising benefits and minimi
- Page 128 and 129:
FC15 Endothelium in Health and dise
- Page 130 and 131:
FC17 New approaches and targets in
- Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
- Page 134 and 135:
W30 Workshop. Is eNOS still a valid
- Page 136 and 137:
W32 Workshop. The good, the bad and
- Page 138 and 139:
W34 Workshop. State-of-the-art of b
- Page 140 and 141:
FC10 Drugs for half the world: Pedi
- Page 142 and 143:
FC12 Ion channelopathies: New windo
- Page 144 and 145:
FC14 Addiction and doping: Neurobio
- Page 146 and 147:
FC16 Natural products: Past and fut
- Page 148 and 149:
FC18 Nuclear receptor targets for t
- Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
- Page 152 and 153:
FC11 G protein-coupled 7TM receptor
- Page 154 and 155:
FC13 Maximising benefits and minimi
- Page 156 and 157:
FC15 Endothelium in health and dise
- Page 158 and 159:
FC17 New approaches and targets in
- Page 160 and 161:
158
- Page 162 and 163:
FC01 Clinical pharmacology in the e
- Page 164 and 165:
FC01 Clinical pharmacology in the e
- Page 166 and 167:
FC02 Transmembrane transport: Persp
- Page 168 and 169:
FC03 Ion channels in analgesia and
- Page 170 and 171:
W12 Experimental pain methods in de
- Page 172 and 173:
FC04 Pharmacoepidemiology, current
- Page 174 and 175:
FC05 Translational science in the m
- Page 176 and 177:
FC05 Translational science in the m
- Page 178 and 179:
FC06 The heart gone wrong; stabiliz
- Page 180 and 181:
FC07 Simulation and data modelling
- Page 182 and 183:
FC08 Developments in the treatment
- Page 184 and 185:
FC09 Inflammation and immunopharmac
- Page 186 and 187:
FC09 Inflammation and immunopharmac
- Page 188 and 189:
FC09 Inflammation and immunopharmac
- Page 190 and 191:
FC13 Maximising benefits and minimi
- Page 192 and 193:
FC13 Maximising benefits and minimi
- Page 194 and 195:
W03 Targeting TRP channels for pain
- Page 196 and 197:
W19 Influence of degeneration and r
- Page 198 and 199:
W19 Influence of degeneration and r
- Page 200 and 201:
W20 Pharmacology education for a su
- Page 202 and 203:
FC01 Clinical pharmacology in the e
- Page 204 and 205:
FC02 Transmembrane transport: Persp
- Page 206 and 207:
FC02 Transmembrane transport: Persp
- Page 208 and 209:
FC04 Pharmacoepidemiology, current
- Page 210 and 211:
FC05 Translational science in the m
- Page 212 and 213:
FC05 Translational science in the m
- Page 214 and 215:
FC06 The heart gone wrong; stabiliz
- Page 216 and 217:
FC07 Simulation and data modelling
- Page 218 and 219:
FC08 Developments in the treatment
- Page 220 and 221:
FC09 Inflammation and immunopharmac
- Page 222 and 223:
FC09 Inflammation and immunopharmac
- Page 224 and 225:
FC09 Inflammation and immunopharmac
- Page 226 and 227:
FC13 Maximising benefits and minimi
- Page 228 and 229:
FC13 Maximising benefits and minimi
- Page 230 and 231:
FC19 General session Tue 361 Analge
- Page 232 and 233:
FC19 General session - Biologics Tu
- Page 234 and 235:
FC19 General session - Haematology
- Page 236 and 237:
FC19 General session - oncology Tue
- Page 238 and 239:
FC19 General session - oncology Tue
- Page 240 and 241:
FC19 General session - Toxicology T
- Page 242 and 243:
W02 Symposium on advances in GI pha
- Page 244 and 245:
W11 New opportunities in the pharma
- Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
- Page 248 and 249:
FC10 Drugs for half the world: Paed
- Page 250 and 251:
FC11 G protein-coupled 7TM receptor
- Page 252 and 253:
FC11 G protein-coupled 7TM receptor
- Page 254 and 255:
FC12 Ion channelopathies: New windo
- Page 256 and 257:
FC13 Maximising benefits and minimi
- Page 258 and 259:
FC13 Maximising benefits and minimi
- Page 260 and 261:
FC14 Addiction and doping: Neurobio
- Page 262 and 263:
FC15 Endothelium in health and dise
- Page 264 and 265:
FC15 Endothelium in health and dise
- Page 266 and 267:
FC15 Endothelium in health and dise
- Page 268 and 269:
W30 Is eNOS Still a valid therapeut
- Page 270 and 271:
FC16 Natural products: Past and fut
- Page 272 and 273:
FC16 Natural products: Past and fut
- Page 274 and 275:
FC16 Natural products: Past and fut
- Page 276 and 277:
FC17 New approaches and targets in
- Page 278 and 279:
FC17 New approaches and targets in
- Page 280 and 281:
W34 State-of-the-art of basic and c
- Page 282 and 283: FC10 Drugs for half the world: Paed
- Page 284 and 285: FC11 G protein-coupled 7TM receptor
- Page 286 and 287: FC11 G protein-coupled 7TM receptor
- Page 288 and 289: FC11 G protein-coupled 7TM receptor
- Page 290 and 291: FC13 Maximising benefits and minimi
- Page 292 and 293: FC13 Maximising benefits and minimi
- Page 294 and 295: W29 New horizons in therapeutic dru
- Page 296 and 297: FC14 Addiction and doping: Neurobio
- Page 298 and 299: FC15 Endothelium in health and dise
- Page 300 and 301: FC15 Endothelium in health and dise
- Page 302 and 303: FC15 Endothelium in health and dise
- Page 304 and 305: FC16 Natural products: Past and fut
- Page 306 and 307: FC16 Natural products: Past and fut
- Page 308 and 309: FC16 Natural products: Past and fut
- Page 310 and 311: FC16 Natural products: Past and fut
- Page 312 and 313: FC17 New approaches and targets in
- Page 314 and 315: FC18 Nuclear receptor targets for t
- Page 316 and 317: 314 Index Name Paper ref. Name Pape
- Page 318 and 319: 316 Index Name Paper ref. Name Pape
- Page 320 and 321: 318 Index Name Paper ref. Name Pape
- Page 322 and 323: 320 Index Name Paper ref. Name Pape
- Page 324 and 325: 322 Index Name Paper ref. Name Pape
- Page 326 and 327: 324 Index Name Paper ref. Name Pape
- Page 328 and 329: 326 Index Name Paper ref. Name Pape
- Page 330 and 331: 328 Index Name Paper ref. Name Pape
- Page 334 and 335: 332 Index Name Paper ref. Name Pape
- Page 336 and 337: 334 Index Name Paper ref. Name Pape
- Page 338 and 339: 336 Index Name Paper ref. Name Pape
- Page 340 and 341: 338 Index Name Paper ref. Name Pape
- Page 342 and 343: 340 Index Name Paper ref. Name Pape
- Page 344 and 345: 342 Index Name Paper ref. Name Pape
- Page 346 and 347: 344 Index Name Paper ref. Name Pape
- Page 348 and 349: 346 Index Name Paper ref. Name Pape
- Page 350 and 351: 348 Index Name Paper ref. Name Pape
- Page 352 and 353: 350 Index Name Paper ref. Name Pape
- Page 354 and 355: 352 Index Name Paper ref. Name Pape
- Page 356 and 357: 354 Index Name Paper ref. Name Pape
- Page 358 and 359: 356 Index Name Paper ref. Name Pape
- Page 360 and 361: 358 Index Name Paper ref. Name Pape
- Page 362 and 363: 360 Index Name Paper ref. Name Pape
- Page 364 and 365: 362 Index Name Paper ref. Name Pape
- Page 366 and 367: 364 Index Name Paper ref. Name Pape
- Page 368 and 369: 366 Index Name Paper ref. Name Pape
- Page 370 and 371: 368 Index Name Paper ref. Name Pape
- Page 372 and 373: 370 Index Name Paper ref. Name Pape
- Page 374 and 375: 372 Index Name Paper ref. Name Pape
- Page 376 and 377: 374 Index Name Paper ref. Name Pape
- Page 378 and 379: 376 Index Name Paper ref. Name Pape
- Page 380 and 381: 378 Index Name Paper ref. Name Pape
- Page 382 and 383:
380 Index Name Paper ref. Name Pape
- Page 384 and 385:
382 Notes Notes
- Page 386:
Final Programme printed in Singapor